Stay updated with breaking news from About Soligenix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix, Inc.: Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin". The allowed claims are directed to unique, proprietary methods to produce a novel, hi...
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma News provided by Share this article Share this article PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Pr...
Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting News provided by Share this article Share this article PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the Uni...
HyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting News provided by Share this article Share this article PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylva...